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Abstract
Background: Abelson interactor 1 (Abi1) is an important regulator of actin dynamics during cytoskeletal reorganization. In
this study, our aim was to investigate the expression of Abi1 in colonic mucosa with and without inflammation, colonic
polyps, colorectal carcinomas (CRC) and metastases as well as in CRC cell lines with respect to BRAF/KRAS mutation status
and to find out whether introduction of KRAS mutation or stimulation with TNFalpha enhances Abi1 protein expression in
CRC cells.
Methodology/Principal Findings: We immunohistochemically analyzed Abi1 protein expression in 126 tissue specimens
from 95 patients and in 5 colorectal carcinoma cell lines with different mutation status by western immunoblotting. We
found that Abi1 expression correlated positively with KRAS, but not BRAF mutation status in the examined tissue samples.
Furthermore, Abi1 is overexpressed in inflammatory mucosa, sessile serrated polyps and adenomas, tubular adenomas,
invasive CRC and CRC metastasis when compared to healthy mucosa and BRAF-mutated as well as KRAS wild-type
hyperplastic polyps. Abi1 expression in carcinoma was independent of microsatellite stability of the tumor. Abi1 protein
expression correlated with KRAS mutation in the analyzed CRC cell lines, and upregulation of Abi1 could be induced by
TNFalpha treatment as well as transfection of wild-type CRC cells with mutant KRAS. The overexpression of Abi1 could be
abolished by treatment with the PI3K-inhibitor Wortmannin after KRAS transfection.
Conclusions/Significance: Our results support a role for Abi1 as a downstream target of inflammatory response and
adenomatous change as well as oncogenic KRAS mutation via PI3K, but not BRAF activation. Furthermore, they highlight a
possible role for Abi1 as a marker for early KRAS mutation in hyperplastic polyps. Since the protein is a key player in actin
dynamics, our data encourages further studies concerning the exact role of Abi1 in actin reorganization upon enhanced
KRAS/PI3K signalling during colonic tumorigenesis.
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Introduction
Worldwide, death from intestinal neoplasms is a high ranking
cause of death from cancer in both male and female populations.
Up to date, fundamental insights into the molecular biology of
tumorigenesis, growth and metastasis were obtained, leading to
today’s sight of an interplay of environmental and genetic causes
finally resulting in the disease along a multi-step process [1,2,3]. In
recent years, different pathways of colorectal carcinogenesis have
been proposed and thoroughly discussed. It has become clear that
certain molecular features, such as APC-, KRAS-, or BRAF-
mutations or microsatellite instability are associated with different
pathways of tumorigenesis, leading to clinically and morpholog-
ically distinct colorectal carcinoma entities [4,5]. The clinical
significance of these molecular alterations and their exact role in
tumorigenesis are still subject to ongoing research [6]. However, it
has been shown that reorganization of the actin cytoskeleton is an
important step in colorectal tumorigenesis, and that the expression
patterns of proteins associated with this reorganization are
significantly altered during the progression from colorectal
adenoma to carcinoma [7]. Abi1, a 65 kD substrate of the
Abelson tyrosine kinase and component of a trimeric complex
consisting of Abi1 and its protein interaction partners Eps8 and
Sos1, is a known adaptor protein involved in actin reorganization
and lamellopodia formation. It has been shown to mediate cell
spreading and migration by interacting with WASP-family
verprolin-homologous protein 2 (WAVE2) [8,9]. Interestingly,
Abi1 has also been shown to act in a multiprotein complex
together with the EGFR/RAS-signalling effector molecule
Phosphatidylinositol-3-kinase (PI3K). The Abi1/PI3K/Eps8/
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Sos1 complex facilitates actin reorganization via activation of Rac
[10]. To mediate its function, Abi1 localizes at the cellular leading
edge of fibroblasts. In neurons, it is located at the postsynaptic
density of maturating synapses, where it supports synaptic
maturation and establishment of the postsynaptic density (PSD)
in early neurogenesis [11,12,13]. In these studies, it has further
been shown that Abi1 translocates from the synapse to the nucleus
after neuronal stimulation and can be precipitated from the
nucleus in a complex with the Myc/Max transcription factor. This
highlights the possibility of an additional, nuclear role of Abi1 in
transcriptional regulation as a part of this transcription-factor
complex.
In tumor tissue and cell lines, it has been shown that Abi1
contributes to leukemogenic potential in leukemic cells expressing
oncogenic Bcr/Abl and v-Abl. RNAi knockdown of Abi1 in these
cells led to impaired cell migration and abnormal actin remodeling
and it has been suggested that these effects might be mediated
through Src family kinases [14]. Consistent with this data, Abi1
seems to be overexpressed in highly invasive breast cancer cell
lines compared to weakly invasive ones, and Abi1 knockdown in
these cells also led to decreased invasiveness and migration ability
[15]. Interestingly, our work group recently identified the
heterogeneous nuclear ribonucleoprotein K (hnRNP K) as one
protein interaction partner of Abi1, while overexpression and
aberrant localization of hnRNP K in tumor cells has previously
been described to be correlated with adverse outcome in colorectal
carcinoma patients [16,17].
In this study, we analyzed the expression pattern of Abi1 in
colonic mucosa with and without inflammation, in colonic
precursor lesions, colorectal carcinoma and colorectal cancer
metastasis and correlated Abi1 expression with the respective
KRAS/BRAF mutation status of each lesion. Furthermore, we
analyzed Abi1 expression status in three widely-used colorectal
carcinoma cell lines with known mutation status as well as in two
colorectal carcinoma cell lines that have been previously
established by our work group [18,19]. Finally, we investigated
the effect of transfection with either KRAS wild-type or KRAS
G12D as well as TNFalpha stimulation and Wortmannin




In general, patients with hyperplastic polyps (HPP) and sessile
serrated polyps/adenomas (SSA/P) were younger (60617.5 y and
59615.3 y, Table 1) and more SSA/P were localized in the right
colon (R:L 12:8). Patients with traditional serrated adenomas and
tubular adenomas were older (7869.8 y and 6465.5 y) and the
lesions were localized in the left rather than in the right colon (R:L
2:6 and 4:9). In general, SSA/P tended to be more expanded (12
of 20 larger than 5 mm).
KRAS and BRAF Mutation Status of Precursor Lesions and
Colorectal Carcinomas
KRAS codon 12 mutations were found in 8/23 hyperplastic
polyps (34.8%) and 3/20 sessile serrated polyps/adenomas (15%,
Table 1; exact mutations are shown in Table S1). BRAF V600E
mutation was detected in 6/23 hyperplastic polyps (26%) and 14/
20 sessile serrated polyps/adenomas (70%). We found KRAS
codon 12 and 13 mutations in half of the traditional serrated
adenomas (4/8, 50%) but could not detect a BRAF mutation in
these lesions. 4 of 13 tubular adenomas (30.8%) carried a KRAS
codon 12 or 13 mutation, while only one tubular adenoma carried
a BRAF codon 600 mutation (7.7%). Among the colorectal
carcinoma specimens, we detected a KRAS codon 12 or 13
mutation in half of the samples (10/20, 50%), but a BRAF codon
600 mutation only in one sample (1/20, 5%). Two of the KRAS-
mutated and the single BRAF-mutated carcinoma showed loss of
nuclear MLH-1 and PMS-2 immunostaining. Two of nine
metastases (25%) carried a KRAS codon 12 mutation. KRAS
and BRAF mutations were mutually exclusive. There was no
correlation between mutation status and either size or origin of the
specimen (p.0.1).
Abi1 Expression in Healthy and Inflamed Mucosa
Abi1 expression score was 2.4661.15 in healthy mucosa (Muc)
and significantly higher (4.061.05) in inflamed mucosa (IM;
Table 2, Fig. 1A, I and Fig. 2; p,0.01, all exact p-values are
shown in Fig. S4). Abi1 staining was localized in the basal
cytoplasm in healthy mucosa, while inflamed mucosa showed a
heterogeneous staining pattern of almost no positivity to strong,
ubiquitous cytoplasmic positivity (Fig. 1 I). Inflammatory cells in
underlying stroma and lymphoid follicles were strongly positive.
There was no statistical significant difference between specimens
from the right (3.1961.52) or left colon (2.5961.12; p.0.1).
Abi1 Expression in Serrated Lesions
Abi1 expression patterns in HPP varied from no expression to
strong, ubiquitous cytoplasmic positivity. Again, underlying
lymphocytes showed strong Abi1 immunoreactivity. Considering
mutation status, there was no significant Abi1 overexpression in
HPP without one of the tested mutations (Table 2, 2.6660.5)
compared to healthy mucosa (p.0.1), but there was significant
lower Abi1 expression score in wild-type HPP compared to
inflamed mucosa (Table 2, Fig. 1 B,I, Fig. 2, p,0.01). HPP with
BRAF V600E mutation (361.26) were not significantly different
from wild-type polyps (p.0.1). In polyps harboring KRAS
mutations, however, mucosal cytoplasmic Abi1 expression score
was significantly increased compared to healthy mucosa and to
wild-type as well as BRAF-mutated HPP (Fig. 3 C, 5.3860.52 vs.
2.4661.15 or 2.6660.47 or 361.26 (p,0.01); Fig. 1 C, Fig. 2–
yellow background). Compared to inflamed mucosa, there was a
statistically significant overexpression of Abi1 (Table 2, Fig. 1 I,
Fig. 2, and Fig. S4, p,0.01). To examine whether this
overexpression in KRAS-mutated HPP was due to an increase
in proliferative activity, we also performed Ki67 immunostaining,
but did not find an enhancement of the proliferative zone in
KRAS-mutated polyps (Fig. S1). There was no statistically
significant difference between Abi1 expression in smaller
(,0.5 cm; 3.4561.29) and larger ($0.5 cm; 3.9161.62) HPP
(p.0.1).
In wild-type sessile serrated polyps/adenomas, Abi1 expression
was 4.6660.58, and therefore significantly higher compared to
healthy mucosa (p,0.01; Fig. 1 A, D and Fig. 2) but not to
inflamed mucosa (Table 2, p.0.1; Fig. 1 D and I). Again, there
was no statistically significant difference between Abi1 expression
in smaller (,0.5 cm; 4.8561.57) and larger ($0.5 cm; 4.2361.42)
SSA/P (p.0.1). Abi1 showed consistent and strong immunoreac-
tivity in mucosal cytoplasm and underlying lymphocytes. Consid-
ering BRAF mutation status, Abi1 expression in SSP/A was not
significant higher in BRAF-mutated lesions (4.6461.01) compared
to wild-type or KRAS-mutated lesions (Table 2, Fig. 2, p.0.1).
Abi1 immunoreactivity was higher in all SSA/P compared to wild-
type and BRAF-mutated HPP, although only slightly significant
(p,0.1). Compared to KRAS-mutated HPP, there was no
difference in Abi1 expression (p.0.1, Fig. 2 B). Wild-type
traditional serrated adenomas had a significantly higher mucosal
Abi1 in Colonic Mucosa, Polyps and Cancer
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Abi1 expression score compared to healthy mucosa, wild-type and
BRAF-mutated HPP, but not to inflamed mucosa and to KRAS-
mutated HPP (Table 2, 5.061.15; p,0.01 and p.0.1, respec-
tively; Fig. 1E and I, Fig. 2). Among TSAs, there was no difference
between KRAS-mutated and wild-type lesions, but KRAS-
mutated TSA had a slightly higher Abi1 expression compared to
IM (5.2560.96; p,0.1). There was no significant difference in
Abi1 expression between SSA/P and TSA in general, and there
was no significant correlation between Abi1 expression and either
size (462.82 vs. 5.1660.98 while only two TSA were smaller than
0.5 cm) or origin of the specimen (p.0.1).
Abi1 Expression in Tubular Adenomas (TbA)
Abi1 was significantly overexpressed in KRAS-mutated TbA
compared to both healthy mucosa or inflamed mucosa (Table 2,
5.7560.96, p,0.01 and p,0.1; Fig. 1 F and I, Fig. 2). There was
also a significant Abi1-overexpression in wild-type TbA
(4.8660.99) compared to healthy mucosa, but not to inflamed
mucosa (p.0.1). There was no statistically significant difference
between Abi1 expression in smaller (,0.5 cm; 5.6661.15) and
larger ($0.5 cm; 560.94) TbA (p.0.1). Compared to HPP, Abi1
expression was stronger in all TbA compared to wild-type and
BRAF-mutated HPP, but similar to KRAS-mutated HPP (p,0.01
and p.0.1, respectively; Fig. 1B–F, Fig. 2). Again, Abi1 showed
strong immunoreactivity in mucosal cytoplasm and underlying
lymphocytes. While there was a slight, but significant overexpres-
sion of Abi1 in TbA compared to BRAF-mutated SSA/P, there
was no difference between TbA and other SSA/P or TSA (p,0.1
and p.0.1, respectively). We only had one BRAF-mutated TbA in
the study, and could therefore not perform statistical testing with
this entity.
Abi1 Expression in Colorectal Carcinoma and Metastasis
Abi1 was strongly and ubiquitously expressed in the cytoplasm
of most examined tumor samples and metastases. Again, there was
a slight, but statistical significant overexpression of Abi1 in the
KRAS-mutated tumors compared to the wild-type group (Table 2,
5.860.79 vs. 4.5661.33, p,0.05, Fig. 1 G,H and Fig. 2). We only
had one BRAF-mutated tumor in the study, and could therefore
not perform statistical testing with this entity. Interestingly, Abi1
expression in KRAS-mutated carcinomas was also higher com-
pared to mucosa, inflamed mucosa, wild-type HPP, SSA/P and
TbA as well as BRAF-mutated SSA/P, but not different from all
TSAs and KRAS-mutated HPP, SSA/P and TbA (Fig. 2, orange
background; see Fig. S4 for exact p-values). There was no
significant difference between specimens from the right (5.061.27)
or left colon (5.261.25, p.0.1) or related to tumor grade (well and
moderate: 5.0961.32; poor: 4.9661.08, respectively; p.0.1).
Furthermore, there was no significant difference in Abi1
expression between microsatellite stable (MSS, n = 17) and instable
(MSI, n = 3) tumors (p.0.1). The expression scores in wild-type
carcinoma (regardless of microsatellite stability) and metastases
were significantly higher compared to healthy mucosa, wild-type
and BRAF-mutated HPP (p,0.05). The difference in Abi1




Mucosa HPP SSP/A TSA TbA Ca Met
Total Patients (n = 95) 23 4 12 14 5 8 20 9
Total samples (n = 126) 24 9 23 20 8 13 20 9
Age 69.5617.7 23621.9 60617.5 59615.3 7869.8 6465.5 68.5610,1 6067,7
Gender (M:F) 13:10 3:1 7:5 5:9 1:4 5:3 12:8 4:2
Location (R:L) 13:11 3:6 11:12 13:7 2:6 4:9 6:14 –
Size (mm) ,5 – – 11 8 2 1 – –
$5 – – 12 12 6 12 – –
BRAF (c600) n.t. n.t. 6 14 .0 1 1 0
KRAS (c12/13) n.t. n.t. 8 3 4 4 10 2
MSS n.t. n.t. 23/23 20/20 8/8 13/13 17/20 9/9
Grading Well – – – – – – 4
Moderate – – – – – – 10 6
Poor – – – – – – 6 3
Stage Dukes A – – – – – – 3 –
Dukes B – – – – – – 6 –
Dukes C – – – – – – 9 –
Dukes D
unknown
– – – – – – 0 9
– – – – – – 2 –
Site Liver – – – – – – – 6
Lung – – – – – – – 2
Others – – – – – – – 1
Abbreviations: HPP: hyperplastic polyp; SSA/P: sessile serrated polyp/adenoma; TSA: traditional serrated adenoma; TbA: tubular adenoma; Ca: invasive colorectal
carcinoma; Met: Metastasis; BRAF c600: B1 Rapidly accelerated fibrosarcoma codon 600 mutation; KRAS c12/13: Kirsten rat sarcoma codon 12 or 13 mutation.; n.t.: not
tested; -: not applicable.
doi:10.1371/journal.pone.0040671.t001
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expression between KRAS-muteted carcinoma and KRAS-
mutated HPP, on the other hand, was not significant (Fig. 2,
p.0.1). Furthermore, the score was not significantly different in
carcinomas and metastases than in TSA (p.0.1). Among
colorectal carcinoma metastases, Abi1 immunohistochemistry
showed the same intense cytoplasmic staining pattern in almost
all examined samples (Fig. 1H). However, there was a statistically
significant decrease in Abi1 expression in KRAS-mutated
metastases compared to KRAS-mutated primary tumors and
HPP (Table 2, 4.560.7; Fig. 2, p,0.1) There was no significant
difference in Abi1 expression score related to the site of metastasis
(p.0.1).
Abi1 Expression in Colorectal Carcinoma Cell Lines
SW620, SW1116 and Colo205
Western blotting showed only very faint bands detected at
65 kD in BRAF-V600E-mutated Colo205 cells, but a strong
double-band in KRAS G12V-mutated SW620 and KRAS G12D-
mutated SW1116 cells, respectively (Fig. 3A, upper panel). Equal
protein loading was shown by ß-Actin immunoblotting (lower
panel). The blot therefore shows a higher expression of Abi1 in the
cell lines harboring KRAS G12V and G12D mutations, but not in
the cell line harboring the BRAF V600E mutation.
Abi1 Expression and KRAS/BRAF Mutation Testing in
CHD-1 and HDC-9 Colorectal Carcinoma Cells
Western blotting with an antibody against Abi1 showed a strong
band at 65 kD in CHD-1 cells, but only a weak signal in HDC-9
cells (Fig. 3B, I, upper panel). Equal amounts of protein were
detected with antibodies against PI3K (85 kD) and ß-Actin
(42 kD) in both cell lysates, while CHD-1 cells showed a slightly
stronger signal for phosphorylated Akt. Treatment of both cell
lines with 50 nM of the PI3K-inhibitor Wortmannin for 72 hours
resulted in an absence of phosphorylated Akt compared to
untreated cells and an almost complete extinction of the Abi1
signal in both cell lines (Lower panels). Immunofluorescence
microscopy showed strong cytoplasmatic and nuclear Abi1
expression in CHD-1 cells (Fig. 3B, II, upper image) compared
to a weak cytoplasmatic signal in HDC-9 cells (lower image). Strip-
assay-based KRAS/BRAF mutation analysis revealed an activat-
ing G13D mutation in the CHD-1 cell line (Fig. 3C, left lane) that
could be tracked to a GGC to GAC point mutation in codon 13 by
subsequent pyrosequencing (Fig. S3, top left pyrogram). The
HDC-9 cell line turned out to carry wild-type KRAS (Fig. 3C,
central lane and Fig. S3, central left pyrogram). Both cell lines are
BRAF codon 600 wild-type as confirmed by strip assay testing and
pyrosequencing (Fig. 3C and Fig S3, right pyrograms).
Transfection Experiments and TNFalpha Treatment in
CHD-1 and HDC-9 Colorectal Carcinoma Cells
We transfected pcDNA3.1 mammalian expression vectors
carrying either wild-type KRAS or G12D-mutated KRAS into
KRAS wild-type HDC-9 cells. Overexpression of KRAS was
shown by pan-Ras immunoblotting (Fig. 3D), while introduction
of the G12D mutation was confirmed by KRAS/BRAF strip assay
testing and pyrosequencing (Fig. 3C, right lane and Fig. S3, lower
left pyrogram). Transfection with the KRAS G12D construct led
to an upregulation of Abi1 as confirmed by western immunoblot-
ting, while there was no increase in protein expression upon
transfection with the wild-type KRAS construct (Fig. 3D, upper
panel, left lanes). Transfection with wild-type KRAS led to an
increase in Akt and Erk1/2 phosphorylation compared to the
control lysate (central panels). The pAkt and pErk1/2 signals were
stronger after KRAS G12D transfection. We then treated HDC-9
cells with 20 ng TNFalpha to simulate an inflammatory setting.
This led to a strong upregulation of Abi1 as was again confirmed
by western blotting (Fig. 3D, upper panel, right). TNFalpha
treatment also enhanced phosphorylation of Akt and Erk1/2. To
show whether Abi1-upregulation depends on PI3K activity, we
treated HDC-9 cells that had previously been transfected with
KRAS G12D with 50 nM of the PI3K-inhibitor Wortmannin for
72 hours. This led to a strong reduction in Abi1-expression
compared to the transfected cells (Fig. 3D, upper panel, far right).
Taken together, these results show an increase in MAPK/PI3K
signaling and an overexpression of Abi1 upon transfection of wild-
type HDC-9 colonic carcinoma cells with constitutively active
KRAS G12D. This upregulation can be hindered by application
of the PI3K-inhibitor Wortmannin. Furthermore, stimulation with
TNFalpha enhances phosphorylation of signaling proteins and
also leads to upregulation of Abi1.
Discussion
Semiquantitative Abi1 Expression Analysis
In this study, we firstly analyzed the expression and distribution
of Abi1, a protein described as an important regulator of actin
dynamics, in healthy and inflamed colonic mucosa and precursor
lesions as well as colorectal adenocarcinoma and metastasis. Of
Table 2. Abi1 expression in analyzed samples.
Abi1 score ± SD n
Healthy Mucosa (HM) 2.46 1.15 24
Right Colon (R) 3.19 1.52 13
Left colon (L) 2.59 1.12 11
Inflamed Mucosa (IM) 4 1.05 9
HPP




HPP KRAS c12/13 5.38 0.52 8
SSA/P SSA/P wt 4.66 0.58 3
SSA/P BRAF c600 4.64 1.01 14
SSA/P KRAS c12/13 5 1 3
TSA TSA wt 5 1.15 4
TSA KRAS c12/13 5.25 0.96 4
TbA TbA wt 4.86 0.99 8
TbA BRAF c600 5 n.a. 1
TbA KRAS c12/13 5.75 0.96 4
Ca Ca wt 4.56 1.33 9
Ca BRAF c600 3 n.a. 1
Ca KRAS c12/13 5.8 0.79 10
Ca MSI 5.33 1.15 3
Met Met wt 5.14 1.07 7
Met KRAS c12/13 4.5 0.7 2
All values shown as mean 6 SD; abbreviations: HPP: hyperplastic polyp; SSA/P:
sessile serrated polyp/adenoma; TSA: traditional serrated adenoma; TbA:
tubular adenoma; Ca: invasive colorectal carcinoma; Met: Metastasis; BRAF c600:
B1 Rapidly accelerated fibrosarcoma codon 600 mutation; KRAS c12/13: Kirsten
rat sarcoma codon 12/13 mutationMSI: microsatellite instable tumors; n:
number of examined samples; n.a.: not applicable due to low sample number.
doi:10.1371/journal.pone.0040671.t002
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course, it cannot be guaranteed that our criteria of inclusion and
exclusion of samples (as described in the Materials and Methods
section) did not cause selection bias among the different diagnosis
groups, and some of the groups (eg. TSA and metastases) are too
small for epidemiologic evaluation. However, it was not the aim of
this study to carry out an extensive epidemiologic analysis of
colonic precursor lesions- all the more since there have been
published excellent studies on this topic [20,21]- but to analyze
Abi1 expression in many different colonic lesions. Clinico-
pathologic analysis of our sample collection showed that patients
with serrated colonic lesions tended to be younger and that the
lesions were localized in the right rather than in the left colon.
These findings are consistent with previously obtained data from
the literature and, although we did not include a vast number of
samples, they support the assumption that the analyzed collection
is representative [4]. The frequency of both BRAF and KRAS
mutations in different colorectal precursor lesions in our study
group reflects data from the literature [22,23,24,25,26,27].
Immunohistochemically, we found weak and basal Abi1
expression in healthy colonic epithelium, with no staining signal
Figure 1. Abi1 immunohistochemistry in colorectal tissue samples. A and B, Regular mucosa (A) and wild-type hyperplastic polyps (B) show
only moderate, cytoplasmatic and basally located Abi1 immunoreactivity. Note intense staining of lymphocytes in subjacent stroma. C,
Overexpression of Abi1 in a representative hyperplastic polyp harboring KRAS G12D mutation. D-F, Intense immunoreactivity in (wild-type) sessile
serrated adenoma (D), traditional serrated adenoma (E) and tubular adenoma (F). Note that positivity for Abi1 is exclusively cytoplasmic. G and H,
strong immunoreactivity for Abi1 in invasive colorectal carcinoma and in a liver metastasis of colorectal carcinoma. I, strong cytoplasmic
immunoreactivity for Abi1 in inflamed colonic mucosa. Stain: anti-Abi1, haematoxylin; Bar indicates 200 mm.
doi:10.1371/journal.pone.0040671.g001
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in the nucleus. This localization pattern might be due to an
interaction with basally localized integrins, since interaction of
Abi1 with both alpha4 and beta1 integrin has been previously
described [28,29]. The strong Abi1 staining of underlying,
interstitial inflammatory cells has also been previously described
and is a helpful positive control [30]. In colonic biopsies with
inflammation, there was a significantly stronger staining signal.
With regard to BRAF and KRAS mutation status in colonic
precursor lesions and invasive carcinomas, wefound that KRAS-
mutated HPP showed significantly higher Abi1 expression
compared to healthy and inflamed mucosa as well as wild-type
and BRAF-mutated HPP. This is interesting because it has been
previously proposed that some sorts of HPP might in fact represent
precursor lesions during the serrated pathway of colon carcino-
gensis [22]. The upregulation of Abi1 in KRAS-mutated but not
BRAF-mutated HPP was not due to an increase in proliferative
activity, since Ki67 staining showed no enhancement of the basal
proliferative zone in KRAS-mutated HPP compared to wild-type
HPP. This finding is consistent with a recent publication that
reported an HPP-like morphologic phenotype, but no expansion
of the basal crypt stem cell population upon KRAS mutation in
affected crypts [31].
Abi1 was strongly expressed in the mucosal cytoplasm of sessile
serrated polyps and adenomas (SSP/A), traditional serrated
adenomas (TSA) and tubular adenomas (TbA) compared to
healthy mucosa, wild-type and BRAF-mutated HPP. Colorectal
carcinoma and colorectal carcinoma metastases showed the
strongest cytoplasmic Abi1 staining with no difference between
microsatellite-stable (MSS) and -instable (MSI) tumors but with
significant overexpression of Abi1 in KRAS-mutated carcinomas
compared to healthy and inflamed mucosa, wild-type and BRAF-
mutated HPP and SSP/A as well as wild-type tubular adenomas
and wild-type invasive carcinomas. These findings are contradic-
tory to results that were recently published by Baba et al, whose
group found downregulation of Abi1 isoforms in different
intestinal cancers compared to mucosa [32]. However, their
Figure 2. Abi1 expression analysis in specimens and cell lysates. A, Distribution of Abi1 expression in healthy and inflamed mucosa,
hyperplastic polyps (HPP), sessile serrated polyps/adenomas (SSA/P), traditional serrated adenomas (TSA), tubular adenomas (TbA), invasive colorectal
carcinoma (Ca) and metastases (Met). All values except BRAF-mutated TbA and carcinoma (each n = 1) are shown in box and whisker plot. Green
squares represent maximum outliers, red squares represent minimum outliers. For inflamed mucosa, median, 1st and 3rd quartile are equal (score = 4).
B, Statistical differences in Abi1 expression among all examined tissue specimens with respect to mutation status and, where applicable,
microsatellite stability of each lesion. The lane for KRAS-mutated HPP is highlighted with a yellow background, the lane for KRAS-mutated invasive
carcinoma is highlighted with a red background. The undermost line shows the number of examined samples in each group. M: healthy mucosa; IM:
inflamed mucosa; HP wt, HP K, HP B: wild-type, KRAS-mutated and BRAF-mutated hyperplastic polyps; SP wt, SP K, SP B: wild-type, KRAS-mutated and
BRAF-mutated sessile serrated polyps/adenomas; TA wt, TA K: wild-type and KRAS-mutated traditional serrated adenomas; TbA wt, TbA K: wild-type and
KRAS-mutated tubular adenomas; CA wt, CA K, CA MI: wild-type, KRAS-mutated and microsatellite-instable carcinomas; Met wt, Met K: wild-type and KRAS-
mutated metastases; n.s.: not significant; *p,0.1;** p,0.05;*** p,0.01.
doi:10.1371/journal.pone.0040671.g002
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results show a different extent of downregulation among the Abi1
isoforms and among different cancers, with the results from colon
cancer being not as clear-cut as the results from stomach cancer.
Furthermore, KRAS/BRAF mutation and inflammation status as
well as histologic grade had not been evaluated in that study.
Our results point rather toward a cytoplasmic upregulation of
Abi1 during colorectal tumorigenesis but interestingly, overex-
Figure 3. Abi1 in colorectal cancer cell lines. A, Abi1 immunoblotting of colorectal carcinoma whole cell line lysates with different KRAS/BRAF
mutation status shows upregulation of Abi1 in KRAS-mutated SW620 and SW1116, but only a faint signal in BRAF-mutated Colo205 cells. B,
Immunoblotting of CHD-1 and HDC-9 cell lysates show overexpression of Abi1 in CHD1 cells, while both cell lines express comparable amounts of
PI3K (I). There is slightly stronger Akt phosphorylation in CHD1 compared to HDC9 cells. Application of 50 nM Wortmannin (WO) almost completely
repressed the pAkt and Abi1 signals. Immunofluorescence microscopy shows strong cytoplasmatic and nuclear Abi1 staining in CHD-1 cells, but only
a faint cytoplasmatic signal in HDC-9 cells (II). C, KRAS/BRAF mutation testing reveals an activating KRAS G13D mutation in CHD-1 (left lane), while
HDC-9 cells are KRAS wild-type (central lane). Transfection of HDC-9 cells with a KRAS G12D-construct leads to appearance of a band indicating a
KRAS G12D-mutation (right lane). Both cell lines are BRAF wild-type. D, Immunoblotting of HDC-9 after transfection, TNFalpha and Wortmannin
treatment shows an increase in pErk1/2 and pAkt and overexpression of Abi1 upon transfection with constitutively active KRAS G12D (2nd lane)
compared to both control (3rd lane) and to transfection with wild-type KRAS (1st lane). Stimulation with TNFalpha also enhances phosphorylation of
signaling proteins and leads to upregulation of Abi1 (4th lane). The overexpression of Abi1 could be reversed by application of 50 nM Wortmannin
(5th lane).
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pression in KRAS-mutated carcinoma and metastasis was not
significant compared to KRAS-mutated precursor lesions. So, in
all precursor lesions and invasive carcinomas, activating KRAS
mutations led to a significant Abi1 overexpression against the
background of the already existing upregulation in consequence of
adenomatous change, perhaps related to enhanced PI3K/Akt
signalling in these lesions [33]. However, it is still questionable why
there was no significant difference in Abi1 expression between
wild-type and KRAS-mutated adenomas (SSA/P, TSA and TbA).
In our opinion, since the DNA for mutation testing was extracted
from a whole biopsy specimen, this finding might be due to the
fact that the fraction of KRAS-mutated cells in these precursor
lesions might be lower than in a specimen that consists mainly of
homogeneous tumor tissue, and Abi1 upregulation upon adeno-
matous change in major parts of the polyp might mask the
stronger Abi1-overexpression in a minor, KRAS-mutated part of
the lesion. This would also explain the strong upregulation that
could be detected among hyperplastic polyps upon KRAS
mutation, since these non-adenomatous lesions lack a ‘‘back-
ground’’ of Abi1 expression.
In Vitro Experiments
In colorectal cancer cell lines, there was strong expression of
Abi1 in lysates from KRAS-mutated cells, but only a very faint
signal in lysate from BRAF-mutated cells. The appearance of a
double-banded signal at 65 kD in Abi1 immunoblotting has been
previously described and most likely represents different phos-
phorylation states of the protein [12,34]. To further confirm these
results, we used two colorectal carcinoma cell lines (CHD-1 and
HDC-9) with yet unknown mutation status that have been
established by our work group in the 1990s [18,19] and found
that the cell line overexpressing Abi1 (CHD-1) carries an
activating mutation in codon 13 of KRAS. Consistent with these
findings was the overexpression of Abi1 upon transfection of
HDC-9 with mutant KRAS (G12D), while there was no effect on
Abi1 expression after transfection with wild-type KRAS. Endog-
enous Abi1 expression in both cell lines as well as overexpression
upon KRAS G12D-transfection in HDC-9 could be suppressed by
application of the PI3K-inhibitor Wortmannin. Taken together,
our in vitro results point towards an upregulation of Abi1 on protein
level upon constitutive activation of KRAS that is Wortmannin-
sensitive. This is supported by multiple previous studies that
characterized the activating effect of oncogenic KRAS on actin
dynamics, sometimes through overexpression of proteins that are
important for actin reorganization [35]. For example, it has been
described that KRAS induces the activity of the small GTPase
Rac, thus modulating colorectal cancer cell adhesion and motility
[36,37]. Rac, on the other hand, has been characterized as a
positive regulator of actin assembly driven by WAVE family
proteins and the associated Abi1/Eps8/Sos1 complex [9,38].
Abi1 Overexpression in Inflammation and Cancer
KRAS-induced upregulation of Abi1 via the Phosphatidylino-
sitol-3-kinase (PI3K)-pathway might explain the BRAF- indepen-
dence of Abi1 expression shown in patient samples and cell lines
and the suppressive effect of Wortmannin. A schematic model for
this possible regulatory pathway is depicted in Fig. 4. Noteworthy,
PI3K has already been shown to form a complex with Abi1, thus
enhancing Rac activity [39,40,10]. This hypothesis would also
explain the observed upregulation of Abi1 upon inflammation in
colonic mucosa since PI3K is a key player in inflammatory
response [41]. Consistent with that, we could show increased Akt
phosphorylation and overexpression of Abi1 upon TNFalpha
stimulation in KRAS wild-type colorectal carcinoma cells. Given
that, a BRAF-independent upregulation of Abi1 via the PI3K-
pathway as a target protein in actin dynamics downstream from
KRAS is easily conceivable. Our finding of Abi1 overexpression
during the development of invasive carcinomas is comparable to
findings made in ovarian cancer, where coexpression of the
trimeric Abi1/SOS1/Eps8-complex is a prerequisite for Rac-
dependent ovarial cancer cell motility upon lysophosphatidic acid
(LPA)-stimulation [42]. Furthermore, Abi1 has been shown to be a
positive regulator of breast cancer cell proliferation, migration and
invasion [15]. For metastases, Iwaya et al. showed in 2007 that
overexpression of the Abi1/WAVE-complex-interactor Arp2 as
well as protein interaction of Arp2/3 with WAVE2 in colonic
carcinoma cells promotes metastasis and introduction of an
activating KRAS mutation enhances the ability of colon adeno-
carcinoma cells to migrate and invade through filopodia formation
and PI3K-dependent Cdc42 activation [43,44] Therefore, Abi1
expression might be associated with epithelial-mesenchymal
transition (EMT) of colon cancer cells as a prerequisite to invasion
and metastasis and consistent with that, the observed downreg-
ulation of Abi1 in established metastases might be due to a reversal
of that process in the context of mesenchymal-epithelial transition
(MET) at the site of metastasis [45]. Compatible with our findings
of low Abi1-expression in BRAF-mutated lesions, the MET
process has just recently been linked to increased RAF signalling in
metastatic breast carcinoma [46].
Noteworthy Abi1 was detected cytoplasmically, but not in the
nucleus by immunohistochemistry. However, in CHD-1 colorectal
carcinoma cells carrying the KRAS G13D mutation, we could
show slight nuclear Abi1 positivity in immunofluorescence
Figure 4. Proposed model for the regulation of actin dynamics
via KRAS, PI3K and Abi1. Ligand-binding to membrane-associated
receptor tyrosine kinase (RTK) leads to an activation of RAS, which is
constitutively activated in mutant KRAS (*). Activated KRAS activates -
among others - both the B1 Rapidly accelerated fibrosarcoma (BRAF)-
and Phosphatidylinositol-3-kinase (PI3K)-pathway, only the latter
leading to activation of the Abi1/Sos1/Eps8 complex. Via activation of
the small GTPase Rac, this leads to reorganization of the actin
cytoskeleton and to a change in cellular shape. RTK: receptor tyrosine
kinase; KRAS: Kirsten rat sarcoma; BRAF: B1 Rapidly accelerated
fibrosarcoma; PI3K: Phosphatidylinositol-3-kinase; Abi1: Abelson interactor
1; Eps8: Epidermal growth factor receptor kinase substrate; Sos1: Son of
sevenless homolog 1; Rac: Ras-related C3 botulinum toxin substrate.
doi:10.1371/journal.pone.0040671.g004
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microscopy. This is interesting because it has previously been
shown that Abi1 is able to shuttle into the nucleus in a
phosphorylation-dependent manner and to interact with nuclear
transcription factors of the Myc/Max family [47,13]. Results
obtained in this study, however, point rather towards a cytoplas-
mic role for Abi1, perhaps as part of the previously mentioned
trimeric Abi1/SOS1/Eps8-complex downstream of PI3K signal-
ling. Since most of the KRAS-mutated lesions analyzed by
immunohistochemistry in this study carried the more frequent
codon 12 mutation, it could be argued that there might be
different signalling patterns in carcinoma cells carrying activating
mutations in codon 13 that might lead to nuclear translocation of
Abi1. This would be supported by recent studies which describe a
different biological behaviour of carcinomas with KRAS codon 13
compared to other mutations [48,49].
Taken together, it has to be pointed out that the upregulation of
Abi1 that we observed is not restricted to carcinogenesis, but can
also be observed in inflammation and in very early lesions that do
not necessarily progress to cancer, such as hyperplastic polyps. In
these polyps and in colorectal carcinomas, there is significant
overexpression of the protein in KRAS-mutated lesions compared
to both wild-type and BRAF-mutated controls. Our findings might
be explained by a common mechanism of Abi1 upregulation via
the PI3K-pathway for which we provide first in vitro evidence.
Furthermore, our findings raise the question of a possible role for
Abi1 in actin dynamics downstream of PI3K during inflammation
and colonic carcinogenesis and finally, indicate a possible
usefulness for Abi1 immunohistochemistry as a marker for early
KRAS mutation in otherwise inconspicuous hyperplastic polyps.
Materials and Methods
Objectives
The objective of this study was
N to analyze Abi1 expression in 33 mucosal samples, 23
hyperplastic polyps, 20 sessile serrated polyps/adenomas, 8
traditional serrated adenomas and 13 tubular adenomas as
well as samples from 20 colorectal carcinomas and 9 colorectal
carcinoma metastases by immunohistochemistry;
N to analyze KRAS codon 12/13 and BRAF codon 600
mutation status as well as expression of mismatch repair
proteins MLH1, PMS2, MLH2 and MSH6 of all included
precursor lesions, carcinomas and metastases;
N to evaluate differences in Abi1 expression by statistical
hypothesis testing;
N to analyze Abi1 expression in 3 established colorectal
carcinoma cell lines with known KRAS/BRAF mutation
and microsatellite status by western immunoblotting
N to analyze Abi1 expression and KRAS/BRAF mutation status
in two additional colorectal carcinoma cell lines (CHD-1 and
HDC-9) that had previously been established by our research
group by western immunoblotting, KRAS/BRAF strip assay
testing and DNA pyrosequencing;
N to investigate the effect of KRAS wild-type and KRAS G12D
transfection as well as treatment with TNFalpha on the
expression of Abi1 and on the phosphorylation status of Akt
and Erk1/2 in KRAS wild-type HDC-9 colorectal carcinoma
cells
N to investigate the effect of the PI3K-inhibitor Wortmannin on
endogenous Abi1 expression in CHD-1 and HDC-9 as well as
after transfection of KRAS wild-type HDC-9 cells with mutant
KRAS.
Tissue Samples
There were 95 patients and 126 tissue samples in the study. All
samples were submitted to the Institute of Pathology of the
University of Ulm, to the Dept. of Pathology of the Bundes-
wehrkrankenhaus Ulm, to the Gemeinschaftspraxis for Pathology,
Augsburg or to the Institute of Pathology, Klinikum Augsburg, for
diagnostic purpose from January 1st, 2006 to December, 31st,
2009. Healthy mucosa samples were obtained from routine
colonoscopies, while inflamed mucosa samples were obtained
from patients with acute episodes of inflammatory bowel disease
(Morbus Crohn or Ulcerative colitis) without evidence for
dysplasia. The specimens were fixed in 10% buffered formalin
and the whole specimen or representative blocks embedded in wax
and sections stained with haematoxylin and eosin. For this study,
hyperplastic polyps (HPP), sessile serrated polyps/adenomas
(SSA/P), traditional serrated adenomas (TSA) and tubular
adenomas (TbA) have been re-reviewed and assigned to a
diagnosis group according to the morphologic criteria reviewed
by Snover in 2011 [4] (K.S., M.J.S, B.M. and K.K.). We refrained
from further sub-dividing hyperplastic polyps morphologically.
Sessile serrated polyps/adenomas with conventional dysplasia or
mucosal carcinoma/carcinoma in situ were excluded from the
study. The same criteria were established for traditional serrated
adenomas and tubular adenomas. Carcinoma samples were taken
from surgical resection specimens and metastasis samples were
taken from diagnostic biopsies. Nuclear expression of mismatch
repair proteins MLH1, PMS2, MLH2, and MSH6 was shown by
immunohistochemistry in precursor lesions, carcinomas and
metastases, indicating microsatellite stability (MSS) in all examined
precursor lesions, metastases and in 17 of 20 invasive colorectal
carcinomas. 3 carcinomas showed loss of MLH1 and PMS2 and
were therefore regarded as microsatellite instable (MSI). The
clinico-pathological characteristics (age, gender, localization of
sampling, sample size, mutation status, and – if applicable - tumor
grade, tumor stage and localization of metastases) of specimens are
summarized in Table 1.
Immunohistochemistry, Image Acquisition and
Expression Analysis
Immunohistochemistry was done as previously described [17].
Mouse monoclonal antibody against Abi1 was obtained from
MBL (Woburn, USA), diluted in antibody diluent (conc. 1:200;
Zytomed Systems, Berlin, Germany) and applied for 60 min at
room temperature. After application of washing buffer (Zytomed),
peroxidase-blocking for 5 min (Zytomed) and a single 2 min buffer
wash, AP-Polymer (Zytomed) was applied for 30 min at room
temperature and followed by further washing with buffer to
remove unbound antibody. Sites of antibody binding were then
detected by Permanent AP Red Chromogen (Zytomed). Other
immunostainings were performed on a BenchMark Autostainer
(Ventana Medical Systems, Tucson, USA). Ready-to-use rabbit
monoclonal primary antibodies (Ki-67 (clone 30–9), CDX-2 (clone
EPR2764Y), Cytokeratin 20 (clone SP33) and Cytokeratin 7 (clone
SP52) optimally diluted according to the manufacturer’s recom-
mendations were purchased from Ventana Medical Systems
(Tucson, USA). Finally, sections were washed in water, lightly
counterstained with haematoxylin, dehydrated and mounted.
Omitting the primary antibody from the immunohistochemical
procedure and replacing it by antibody diluent acted as negative
control. The sections were evaluated by light microscopic
examination using a Leica DM6000B light microscope (Leica,
Wetzlar, Germany). The intensity of immunostaining in each
section was assessed independently by two observers (K.S. and
B.M., blinded to mutation status) using the scoring system
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described. Both the intensity of immunostaining and the propor-
tion of positively stained cells were assessed. The intensity of
immunostaining was graded as negative = 0, weak = 1, moder-
ate = 2 or strong = 3 [50]. The proportion of positively stained cells
was assessed as no cells = 0, 1–25% of cells = 1, 26–50% = 2, 51–
75% = 3 and 76–100% = 4. The numbers representing intensity
and percentage of stained cells were added together and the result
will be referred to as score. Image acquisition was performed using
a Leica DM6000B light microscope (Leica, Wetzlar, Germany)
and the Diskus Mikroskopische Diskussion image acquisition
software (Carl H. Hilgers, Königswinter, Germany).
Statistics
Expression level differences between diagnostic groups were
assessed by t-test for unpaired data. Testing was performed with
Microsoft Excel (Microsoft, Seattle, USA). All p-values were
considered two-tailed and 0.1 was used as upper threshold for
statistical significance. Graphical display in box and whisker plot
was done using the Box Plot Template for Excel by Vertex42
(Albuquerque, USA – www.vertex42.com).
KRAS and BRAF Mutation Analysis
We examined all precursor lesions (HPP, SSA/P, TSA, TbA),
carcinomas and metastases as well as the 5 included colorectal
carcinoma cell lines for mutation status of KRAS and BRAF.
Samples were excluded when quantity or quality of the material
did not allow DNA extraction or mutation analysis, or the results
of mutation analysis were not clear-cut. DNA was extracted from
30 mm-thick slides that were cut off paraffin blocks, xylene treated
and ethanol washed as previously described [51]. PCR amplifi-
cation of KRAS and BRAF with biotinylated primers and
hybridization-based mutation analysis was performed using the
KRAS/BRAF strip assay (Vienna Labs, Vienna, Austria and AID
diagnostics, Strassberg, Germany) according to the manufacturers’
protocols. For comparison, we grouped the activating mutations as
follows: KRAS codon 12 (Gly.Ala, Arg, Asp, Cys, Ile, Leu, Ser,
Val) and KRAS codon 13 (Gly.Asp,Cys) as KRASc12/13 and
BRAF codon 600 (Val.Glu) as BRAFc600. KRAS/BRAF
mutation analysis in cell lines was repeated by DNA pyrosequenc-
ing. Therefore, cells were lysed in standard lysis buffer and single-
stranded DNA was created using the PyroMark Q24 Vacuum
Workstation (Qiagen, Hilden, Germany). Pyrosequencing was
then performed on the PyroMark Q24 System using the
therascreen KRAS and BRAF Pyro Kits (all Qiagen, Hilden,
Germany) according to the manfacturer’s protocol. Data analysis
and creation of pyrograms was done using the PyroMark Q24
Software 2.0 (Qiagen, Hilden, Germany).
Cell Culture, Transfection Experiments and Western Blot
Human colorectal carcinoma cell lines SW620, SW1116 and
Colo205 were obtained from ATCC (Rockville, USA). Colon
carcinoma cell lines CHD-1 and HDC-9 were established from
freshly isolated tumor cells by one of us (S.B.) and have been
previously characterized [18,19]. Derivation of CHD-1 and HDC-
9 from colorectal carcinoma was reassured by immunohistochem-
istry for CDX2, Cytokeratin 7 and Cytokeratin 20 (Fig. S2).
SW620, SW1116 and Colo205 are microsatellite stable (MSS), for
CHD-1 and HDC-9 microsatellite stability was proven by positive
nuclear immunostaining of mismatch repair proteins MLH1,
PMS2, MLH2, and MSH6 (data not shown). Cells were
maintained in DMEM supplemented with 10% FCS. Transfection
experiments were performed using the Optifect transfection
reagent (Invitrogen, Karlsruhe, Germany) according to the
manufacturer’s recommendations 36 hours prior to cell lysis in
medium without serum and antibiotics. TNFalpha (SignalChem,
Richmond, Canada) was added in 2 doses of each 10 ng 24 and 12
hours prior to cell lysis. Wortmannin (AppliChem, Darmstadt,
Germany) was added to a final concentration of 50 nM for 72
hours after KRAS transfection. Cells cultured at normal condi-
tions and/or after transfection/TNFalpha/Wortmannin treat-
ment were lysed in standard lysis buffer containing kinase and
phosphatase inhibitors. The supernatants were collected by
centrifugation at 10.000 x g for 5 min at 4uC. Overexpression of
KRAS was tested by Ras immunoblotting, and successful insertion
of mutated KRAS into HDC-9 cells was proven by mutation
testing using the KRAS/BRAF strip assay and DNA pyrose-
quencing (Fig. 3C, right lane and Fig. S3, lower left pyrogram).
For protein detection, 10 mg of total protein was separated by a
10% SDS gel. Immunoblot analysis was done according to
standard methods using the following antibodies: anti-Abi1 (mouse
monoclonal, conc. 1:1.000, MBL, Woburn, USA), anti-PI3K(p85)
(mouse monoclonal, conc. 1:1.000, Abcam, Cambridge, UK),
anti-Ras (rabbit monoclonal, conc. 1:1000, Cell Signaling Tech.,
Boston, USA), anti-phospho-Akt(Ser473) (rabbit monoclonal,
conc. 1:1000, Cell Signaling Tech., Boston, USA) and anti-
phospho-p44/42 MAPK (Erk1/2) (rabbit monoclonal, conc.
1:1000, Cell Signaling Tech., Boston, USA). ß-Actin was used as
a loading control (conc. 1:10.000, mouse monoclonal antibody
against ß-Actin, Abcam, Cambridge, UK).
Expression Vectors
The pcDNA3-KRAS-wild type and pcDNA3-KRAS-G12D
vectors were a kind gift of Dr. Patrizio Castagnola, National
Cancer Research Center, Genova, Italy, and have been previously
published [52]. The constructs contain either the complete cds
sequences for KRAS wild-type or KRASG12D (GGT/GAT
transition) inserted in a mammalian pcDNA3.1 expression vector.
Immunofluorescence Microscopy
Immunocytochemistry was performed as previously described
by our work group [13]. In brief, cultured cells were fixed with ice-
cold Methanol and permeabilized in a buffer containing 0.2%
Triton-X-100/0.1% Na-Citrate/PBS. Blocking was then per-
formed with 10% FCS/PBS for 1 h at RT followed by one hour
incubation with the primary and secondary antibodies and
mounting in vectashield aqueous mount (Vector, USA). Cell
nuclei were counterstained with 4,6-diamidino-2-phenylindole
(DAPI). The primary antibody was anti-Abi-1 (mouse monoclonal,
conc. 1:250, MBL, Woburn, USA). The fluorescence-labeled
secondary antibody was Alexa FluorH 568 (red, used filter set:
excitation BP 534 nm–558 nm, FT 560, emission BP 575 - 640).
Image acquisition was performed using a Leica DM6000B light
microscope (Leica, Wetzlar, Germany) and the Diskus Mikrosko-
pische Diskussion image acquisition software (Carl H. Hilgers,
Königswinter, Germany).
Ethics
All tissue samples were collected for histologic examination and
diagnosis purpose and anonymized for the use in this study.
Informed consent was therefore not needed to be obtained. This
was approved by the ethics committee of the University of Ulm
and conforms to the current guidelines of the German Ethics
Council [53].
Supporting Information
Figure S1 Ki67 expression in KRAS-wild type and
KRAS-mutated hyperplastic polyps. A and B, both polyps
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show only basal positivity for Ki67. There is no expansion of the
proliferative zone in KRAS-mutated HPP. Stain: anti-Ki67,
haematoxylin; Bar indicates 200 mm.
(TIF)
Figure S2 Immunohistochemical characterization of
CHD-1 and HDC-9 cells. Both cell lines stain positive for
CDX-2 and cytokeratin 20 and negative for cytokeratin 7. Stain:
haematoxylin/eosin, anti-CDX2, anti-cytokeratin 7, anti-cytokeratin 20 as
indicated; Bar indicates 25 mm.
(TIF)
Figure S3 Pyrosequencing data from CHD-1 and HDC-9
cells. The upper left pyrogram shows an activating G13D
mutation in the CHD-1 cell line (arrowhead), while HDC-9 cells
are KRAS wild-type (central left pyrogram). Transfection of
HDC-9 cells with a KRAS G12D-construct leads to appearance of
a small peak, indicating a KRAS G12D-mutation (lower left
pyrogram, arrowhead). Both cell lines are BRAF wild-type (right
pyrograms).
(TIF)
Figure S4 Exact p-values from statistical hypothesis
testing. See Fig. 3 B for graphical display.
(TIF)
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